Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis

被引:14
|
作者
Dietze, R [1 ]
Fowler, VG
Steiner, TS
Pecanha, PM
Corey, GR
机构
[1] Univ Fed Espirito Santo, Ctr Biomed, Dept Social Med, Vitoria, Brazil
[2] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA
来源
关键词
D O I
10.4269/ajtmh.1999.60.837
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Although amphotericin B desoxycholate is considered the most effective treatment for disseminated Paracoccidioides brasiliensis infections, little is known about the efficacy of lipid-based formulations of amphotericin B in this infection. In this study, we treated four adults with the juvenile form of paracoccidioidomycosis with 3 mg/ kg/day of amphotericin B colloidal dispersion for at least 28 days. Although all of the patients initially responded by clinical observation, all four patients relapsed within six months. The use of amphotericin B colloidal dispersion for the initial induction of paracoccidioidomycosis failed to cure this infection. Possible reasons for failure include dose, duration, or reduced efficacy of this lipid preparation. For many fungal infections, lipid-based preparations have been shown to have a therapeutic-toxic advantage, but our experience with Paracoccidioides infections suggests that more careful studies will need to be performed before they can be recommended for use in this mycosis.
引用
收藏
页码:837 / 839
页数:3
相关论文
共 50 条
  • [1] Treatment of visceral leishmaniasis with Amphotericin B Colloidal Dispersion
    Berman, J
    Dietze, R
    CHEMOTHERAPY, 1999, 45 : 54 - 66
  • [2] Treatment of candidemia with amphotericin B colloidal dispersion.
    Noskin, GA
    Coffey, G
    Gurwith, M
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 78 - 78
  • [3] Amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia
    Roland, WE
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (04) : 935 - 935
  • [4] Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients
    Noskin, GA
    Pietrelli, L
    Coffey, G
    Gurwith, M
    Liang, LJ
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) : 461 - 467
  • [5] Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis
    Sundar, S
    Mehta, H
    Chhabra, A
    Singh, V
    Chauhan, V
    Desjeux, P
    Rai, M
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (05) : 608 - 613
  • [6] Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion
    Beovic, B
    LejkoZupanc, T
    Pretnar, J
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (07) : 507 - 511
  • [7] Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion
    B. Beović
    T. Lejko-Zupanc
    J. Pretnar
    European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16 : 507 - 511
  • [8] Safety of amphotericin B colloidal dispersion
    Herbrecht, R
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (01) : 74 - 80
  • [9] Safety of amphotericin B colloidal dispersion
    R. Herbrecht
    European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16 : 74 - 80
  • [10] Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion
    Vogelsinger, Helene
    Weiler, Stefan
    Djanani, Angela
    Kountchev, Jordan
    Bellmann-Weiler, Rosa
    Wiedermann, Christian J.
    Bellmann, Romuald
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (06) : 1153 - 1160